Abstract
To the Editor: Laboratory panels for myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are increasingly being used in the diagnosis and prognostication of dermatomyositis (DM).1,2 However, many commercial panels used in clinical settings have limited validation compared to other methodologies.3 To understand the accuracy of commercial myositis panels in the clinical setting, we performed a cross-sectional analysis of patients with DM, comparing commercially available myositis panels to panels performed in the research setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
